111 related articles for article (PubMed ID: 26381750)
1. In vitro Study of a Novel Stent Coating Using Modified CD39 Messenger RNA to Potentially Reduce Stent Angioplasty-Associated Complications.
Abraham MK; Nolte A; Reus R; Behring A; Zengerle D; Avci-Adali M; Hohmann JD; Peter K; Schlensak C; Wendel HP; Krajewski S
PLoS One; 2015; 10(9):e0138375. PubMed ID: 26381750
[TBL] [Abstract][Full Text] [Related]
2. Central role of Sp1-regulated CD39 in hypoxia/ischemia protection.
Eltzschig HK; Köhler D; Eckle T; Kong T; Robson SC; Colgan SP
Blood; 2009 Jan; 113(1):224-32. PubMed ID: 18812468
[TBL] [Abstract][Full Text] [Related]
3. Functional analysis of expression of human ecto-nucleoside triphosphate diphosphohydrolase-1 and/or ecto-5'-nucleotidase in pig endothelial cells.
De Giorgi M; Pelikant-Malecka I; Sielicka A; Slominska EM; Giovannoni R; Cinti A; Cerrito MG; Lavitrano M; Smolenski RT
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):313-8. PubMed ID: 24940685
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of platelet recruitment by endothelial cell CD39/ecto-ADPase: significance for occlusive vascular diseases.
Marcus AJ; Broekman MJ; Drosopoulos JH; Pinsky DJ; Islam N; Maliszewsk CR
Ital Heart J; 2001 Nov; 2(11):824-30. PubMed ID: 11770867
[TBL] [Abstract][Full Text] [Related]
5. CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia.
Pulte D; Olson KE; Broekman MJ; Islam N; Ballard HS; Furman RR; Olson AE; Marcus AJ
J Transl Med; 2007 May; 5():23. PubMed ID: 17480228
[TBL] [Abstract][Full Text] [Related]
6. CD39+ regulatory T cells attenuate allergic airway inflammation.
Li P; Gao Y; Cao J; Wang W; Chen Y; Zhang G; Robson SC; Wu Y; Yang J
Clin Exp Allergy; 2015 Jun; 45(6):1126-37. PubMed ID: 25728362
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39.
Gayle RB; Maliszewski CR; Gimpel SD; Schoenborn MA; Caspary RG; Richards C; Brasel K; Price V; Drosopoulos JH; Islam N; Alyonycheva TN; Broekman MJ; Marcus AJ
J Clin Invest; 1998 May; 101(9):1851-9. PubMed ID: 9576748
[TBL] [Abstract][Full Text] [Related]
8. Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: implications for ischemic vascular diseases.
Marcus AJ; Broekman MJ; Drosopoulos JH; Islam N; Pinsky DJ; Sesti C; Levi R
J Pharmacol Exp Ther; 2003 Apr; 305(1):9-16. PubMed ID: 12649347
[TBL] [Abstract][Full Text] [Related]
9. The nucleoside triphosphate diphosphohydrolase-1/CD39 is incorporated into human immunodeficiency type 1 particles, where it remains biologically active.
Barat C; Martin G; Beaudoin AR; Sévigny J; Tremblay MJ
J Mol Biol; 2007 Aug; 371(1):269-82. PubMed ID: 17560607
[TBL] [Abstract][Full Text] [Related]
10. Fingolimod increases CD39-expressing regulatory T cells in multiple sclerosis patients.
Muls N; Dang HA; Sindic CJ; van Pesch V
PLoS One; 2014; 9(11):e113025. PubMed ID: 25411844
[TBL] [Abstract][Full Text] [Related]
11. Structural elements and limited proteolysis of CD39 influence ATP diphosphohydrolase activity.
Schulte am Esch J; Sévigny J; Kaczmarek E; Siegel JB; Imai M; Koziak K; Beaudoin AR; Robson SC
Biochemistry; 1999 Feb; 38(8):2248-58. PubMed ID: 10029517
[TBL] [Abstract][Full Text] [Related]
12. RNA-Eluting Surfaces for the Modulation of Gene Expression as A Novel Stent Concept.
Koenig O; Zengerle D; Perle N; Hossfeld S; Neumann B; Behring A; Avci-Adali M; Walker T; Schlensak C; Wendel HP; Nolte A
Pharmaceuticals (Basel); 2017 Feb; 10(1):. PubMed ID: 28208634
[TBL] [Abstract][Full Text] [Related]
13. The transgenic expression of human CD39 on murine islets inhibits clotting of human blood.
Dwyer KM; Mysore TB; Crikis S; Robson SC; Nandurkar H; Cowan PJ; D'Apice AJ
Transplantation; 2006 Aug; 82(3):428-32. PubMed ID: 16906044
[TBL] [Abstract][Full Text] [Related]
14. Apyrase protects against allergic airway inflammation by decreasing the chemotactic migration of dendritic cells in mice.
Li P; Cao J; Chen Y; Wang W; Yang J
Int J Mol Med; 2014 Jul; 34(1):269-75. PubMed ID: 24804736
[TBL] [Abstract][Full Text] [Related]
15. Constraints imposed by transmembrane domains affect enzymatic activity of membrane-associated human CD39/NTPDase1 mutants.
Musi E; Islam N; Drosopoulos JH
Arch Biochem Biophys; 2007 May; 461(1):30-9. PubMed ID: 17374358
[TBL] [Abstract][Full Text] [Related]
16. Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice.
Jackson SW; Hoshi T; Wu Y; Sun X; Enjyoji K; Cszimadia E; Sundberg C; Robson SC
Am J Pathol; 2007 Oct; 171(4):1395-404. PubMed ID: 17823293
[TBL] [Abstract][Full Text] [Related]
17. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs.
Reutershan J; Vollmer I; Stark S; Wagner R; Ngamsri KC; Eltzschig HK
FASEB J; 2009 Feb; 23(2):473-82. PubMed ID: 18838482
[TBL] [Abstract][Full Text] [Related]
18. Platelets induce CD39 expression in tumor cells to facilitate tumor metastasis.
Ning Z; Liu K; Zhang H; Dong G; Wang X; Xiong H
Br J Cancer; 2024 May; 130(9):1542-1551. PubMed ID: 38461171
[TBL] [Abstract][Full Text] [Related]
19. Increased CD39 expression on CD4(+) T lymphocytes has clinical and prognostic significance in chronic lymphocytic leukemia.
Perry C; Hazan-Halevy I; Kay S; Cipok M; Grisaru D; Deutsch V; Polliack A; Naparstek E; Herishanu Y
Ann Hematol; 2012 Aug; 91(8):1271-9. PubMed ID: 22349724
[TBL] [Abstract][Full Text] [Related]
20. The expression of CD39 on regulatory T cells is genetically driven and further upregulated at sites of inflammation.
Rissiek A; Baumann I; Cuapio A; Mautner A; Kolster M; Arck PC; Dodge-Khatami A; Mittrücker HW; Koch-Nolte F; Haag F; Tolosa E
J Autoimmun; 2015 Apr; 58():12-20. PubMed ID: 25640206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
